Skip to main content
SpringerLink
Log in

Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

The efficiency of dendritic cell-activated and cytokine-induced killer cell (DC-CIK) therapy on children with acute myeloid leukemia (AML) after chemotherapy was investigated. Mononuclear cells were collected from children achieving complete remission after chemotherapy, cultured in vitro and transfused back into the same patient. Interleukin-2 (IL-2) was injected subcutaneously every other day 10 times at the dose of 1×106 units. Peripheral blood lymphocyte subsets and minimal residual disease (MRD) were detected by flow cytometry. Function of bone marrow was monitored by methods of morphology, immunology, cytogenetics and molecular biology. The side effects were also observed during the treatment. The average follow-up period for all the 22 patients was 71 months and relapse occurred in two AML patients (9.1%). The percentage of CD3+/CD8+ cells in peripheral blood of 15 patients at the 3rd month after DC-CIK treatment (36.73%±12.51%) was dramatically higher than that before treatment (29.20%±8.34%, P<0.05). The MRD rate was >0.1% in 5 patients before the treatment, and became lower than 0.1% 3 months after the treatment. During the transfusion of DC-CIK, side effects including fever, chills and hives appeared in 7 out of 22 (31.82%) cases but disappeared quickly after symptomatic treatments. There were no changes in electrocardiography and liver-renal functions after the treatment. MRD in children with AML can be eliminated by DC-CIK therapy which is safe and has fewer side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am, 2010,24(1):35–63

    Article  PubMed  Google Scholar 

  2. Rubnitz JE, Inaba H, Dahl D, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol, 2010,11(6):543–552

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Sievers EL, Radich JP. Detection of minimal residual disease in acute leukemia. Curr Opin Hematol, 2000,7(4):212–216

    Article  CAS  PubMed  Google Scholar 

  4. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep, 2010,5(3):169–176

    Article  PubMed  Google Scholar 

  5. Jorgensen JL, Chen SS. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications. Clin Lymphoma Myeloma Leuk, 2011,11(Suppl 11):49–53

    Article  Google Scholar 

  6. Shook D, Coustan-Smith E, Ribeiro RC, et al. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma, 2009,9(Suppl 3):281–285

    Article  Google Scholar 

  7. Wayne AS, Baird K. Egeler RM. Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am, 2010,57(1):1–25

    Article  PubMed Central  PubMed  Google Scholar 

  8. Marten A, Renoth S, Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica, 2001,86(10):1029–1037

    CAS  PubMed  Google Scholar 

  9. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma, 2003,44(9):1457–1462

    Article  CAS  PubMed  Google Scholar 

  10. Wang QJ, Wang H, Pan K, et al. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer, 2010,29(7):641–648

    Article  PubMed  Google Scholar 

  11. Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother, 2011,60(10):1497–1502

    Article  CAS  PubMed  Google Scholar 

  12. Tan G, Zhang X, Feng H, et al. The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Clin Dev Immunol, 2011:649359

    Google Scholar 

  13. Wei XC, Zhai XH, Han XR, et al. Influence of dendritic cells on biological activity of the homologous CIK cells and its anti-leukemia effect in vitro. Zhong Guo Shi Yan Xue Ye Xue Za Zhi (Chinese), 2010,18(4):946–951

    CAS  Google Scholar 

  14. Li J, Gu LJ, Xue HL, et al. Response rate of AML-XH-99 protocol in the treatment of 82 childhood acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2004,25(6):351–354

    Google Scholar 

  15. Leymarie V, Galoisy AC, Falkenrodt A, et al. Diagnosis of myeloid hematologic malignancies: contributions of the 2001 World Health Organization (WHO) classification. Ann Biol Clin (Paris), 2004,62(5):513–520

    CAS  Google Scholar 

  16. Saglio G. Minimal residual disease detection in human leukemias: biologic and clinical significance. Acta Haematol Pol, 1995,26(2Suppl 1):19–24

    CAS  PubMed  Google Scholar 

  17. Su X, Zhang L, Jin L, et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J Clin Immunol, 2010,30 (5):766–774

    Article  CAS  PubMed  Google Scholar 

  18. van den Ancker W, van Luijn MM, Westers TM, et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy, 2010,2(1):69–83

    Article  PubMed  Google Scholar 

  19. Takei F. LAK cell therapy of AML: not to be lost in translation. Exp Hematol, 2011,39(11):1045–1046

    Article  CAS  PubMed  Google Scholar 

  20. Suck G. Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol, 2006,16(5):412–418

    Article  CAS  PubMed  Google Scholar 

  21. Vauleon E, Avril T, Collet B, et al. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol, 2010;2010. pii: 689171. [Epub 2010 Oct 4] doi: 10.1155/2010/689171

    Google Scholar 

  22. Kadowaki N. Dendritic cells: a conductor of T cell differentiation. Allergol Int, 2007,56(3):193–199

    Article  CAS  PubMed  Google Scholar 

  23. Seo MJ, Kim GR, Son YM, et al. Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells. Mol Immunol, 2011,48(15–16):1744–1752

    Article  CAS  PubMed  Google Scholar 

  24. Chen ZC, Li JY, Yao JX, et al. Dendriticcell-activated and cytokine-induced killer cells therapy for the treatment of acute mylocytic leukemia previously given auto-PBSCT. Linchuang Neike Zazhi (Chinese), 2007,24(9):596–598

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Yan Bai  (白 燕), Nan Wang  (王 楠), He-hua Cai  (蔡荷花), Li-na Zhai  (翟丽娜), Fang Wang  (王 芳), Run-ming Jin  (金润铭) & Dong-feng Zhou  (周东风)

  2. Stem Cell Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Jin-e Zheng  (郑金娥)

  3. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Yao-hui Wu  (吴耀辉)

Authors
  1. Yan Bai  (白 燕)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin-e Zheng  (郑金娥)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nan Wang  (王 楠)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. He-hua Cai  (蔡荷花)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-na Zhai  (翟丽娜)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yao-hui Wu  (吴耀辉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fang Wang  (王 芳)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Run-ming Jin  (金润铭)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dong-feng Zhou  (周东风)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-feng Zhou  (周东风).

Additional information

The first two authors contributed equally to this manuscript.

This project was supported by grants from the National Natural Science Foundation of China (No. 81000211) and Important Research Project from Health Department of Hubei Province, China (No. JX4A05).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bai, Y., Zheng, Je., Wang, N. et al. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 689–693 (2015). https://doi.org/10.1007/s11596-015-1491-5

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-015-1491-5

Key words

Search

Navigation